Q32 Bio (QTTB) 25th Annual Needham Virtual Healthcare Conference summary

Company overview and pipeline

• Focuses on immune and inflammatory diseases, aiming to rebalance the immune system with lead asset bempikibart in phase II for alopecia areata, with mid-year data expected.

• Additional research programs are ongoing, with future updates anticipated.

Mechanism of action and therapeutic rationale

• Bempikibart is a bifunctional antibody targeting IL-7 and TSLP receptor alpha, modulating both autoimmune and allergic pathways.

• Demonstrates full receptor occupancy in studies, potentially enabling broad disease coverage.

Alopecia areata landscape and unmet needs

• Current AA treatments are limited, especially for moderate to severe cases; JAK inhibitors have black box warnings and require frequent monitoring.

• Substantial unmet need exists for safer, effective alternatives; bempikibart aims to fill this gap.